Authors: Vania Denise Djunaidy, Didik Hasmono
Department of Clinical Pharmacy, Faculty of Pharmacy,
Airlangga University Dharmawangsa Dalam, 60286 Surabaya, Indonesia
Email: vaniadenise@hotmail.co.id
Abstract
Eosinophils are primary proinflammatory cells that have an important role to the inflammation in allergic diseases including asthma. Eosinophilic asthma is a phenotype of asthma which characterized by the persistence eosinophils in the airways. Interleukin-5 (IL-5) plays a key role in eosinophil activation and survival. Elevated numbers of blood eosinophils are risk factor for asthma exacerbations. The complexity of chronic severe asthma with various underlying mechanisms suggests that phenotyping patients with severe asthma and individualized therapy could lead to improved treatment outcomes and fewer side-effects. Reslizumab which is a human monoclonal antibody that disrupts eosinophils maturation dan promotes apoptosis estimated can be a potential treatment for poorly controlled eosinophilic asthma. Recently, more clinical trials have been performed to evaluate the effects of anti-interleukin (IL)-5 antibodies in eosinophilic asthma as since 2016, an intravenous formulation of reslizumab was approved by FDA as add-on maintenance treatment for patients aged ≥ 18 years with severe eosinophilic asthma. However, a confirm conclusion has not been well established. In this study, we aimed to review the use of Reslizumab in patients with inadequately controlled, moderate-to-severe asthma.
Keywords: Asthma, Eosinophil, Anti Interleukin 5, Reslizumab
